

	All patients (n=41)	ICU care (n=13)	No ICU care (n=28)	p value
White blood cell count, x 10 ⁹ /L	6.2 (4.1-10.5)	11.3 (5.8-12.1)	5.7 (3.1-7.6)	0.011
<4	10/40 (25%)	1/13 (8%)	9/27 (33%)	0.041
4-10	18/40 (45%)	5/13 (38%)	13/27 (48%)	..
>10	12/40 (30%)	7/13 (54%)	5/27 (19%)	..
Neutrophil count, x 10 ⁹ /L	5.0 (3.3-8.9)	10.6 (5.0-11.8)	4.4 (2.0-6.1)	0.00069
Lymphocyte count, x 10 ⁹ /L	0.8 (0.6-1.1)	0.4 (0.2-0.8)	1.0 (0.7-1.1)	0.0041
<1.0	26/41 (63%)	11/13 (85%)	15/28 (54%)	0.045
≥1.0	15/41 (37%)	2/13 (15%)	13/28 (46%)	..
Haemoglobin, g/L	126.0 (118.0-140.0)	122.0 (111.0-128.0)	130.5 (120.0-140.0)	0.20
Platelet count, x 10 ⁹ /L	164.5 (131.5-263.0)	196.0 (165.0-263.0)	149.0 (131.0-263.0)	0.45
<100	2/40 (5%)	1/13 (8%)	1/27 (4%)	0.45
≥100	38/40 (95%)	12/13 (92%)	26/27 (96%)	..
Prothrombin time, s	11.1 (10.1-12.4)	12.2 (11.2-13.4)	10.7 (9.8-12.1)	0.012
Activated partial thromboplastin time, s	27.0 (24.2-34.1)	26.2 (22.5-33.9)	27.7 (24.8-34.1)	0.57
D-dimer, mg/L	0.5 (0.3-1.3)	2.4 (0.6-14.4)	0.5 (0.3-0.8)	0.0042
Albumin, g/L	31.4 (28.9-36.0)	27.9 (26.3-30.9)	34.7 (30.2-36.5)	0.0066
Alanine aminotransferase, U/L	32.0 (21.0-50.0)	49.0 (29.0-115.0)	27.0 (19.5-40.0)	0.038
Aspartate aminotransferase, U/L	34.0 (26.0-48.0)	44.0 (30.0-70.0)	34.0 (24.0-40.5)	0.10
≤40	26/41 (63%)	5/13 (38%)	21/28 (75%)	0.025
>40	15/41 (37%)	8/13 (62%)	7/28 (25%)	..
Total bilirubin, mmol/L	11.7 (9.5-13.9)	14.0 (11.9-32.9)	10.8 (9.4-12.3)	0.011
Potassium, mmol/L	4.2 (3.8-4.8)	4.6 (4.0-5.0)	4.1 (3.8-4.6)	0.27
Sodium, mmol/L	139.0 (137.0-140.0)	138.0 (137.0-139.0)	139.0 (137.5-140.5)	0.26

残念ながら一般の血液検査では事前に重症化は予測できません。D-ダイマーは？
但し、合併症の有無を調べるには大事です。

Creatinine, $\mu\text{mol/L}$	74.2 (57.5-85.7)	79.0 (53.1-92.7)	73.3 (57.5-84.7)	0.84
≤133	37/41 (90%)	11/13 (85%)	26/28 (93%)	0.42
>133	4/41 (10%)	2/13 (15%)	2/28 (7%)	..
Creatine kinase, U/L	132.5 (62.0-219.0)	132.0 (82.0-493.0)	133.0 (61.0-189.0)	0.31
≤185	27/40 (68%)	7/13 (54%)	20/27 (74%)	0.21
>185	13/40 (33%)	6/13 (46%)	7/27 (26%)	..
Lactate dehydrogenase, U/L	286.0 (242.0-408.0)	400.0 (323.0-578.0)	281.0 (233.0-357.0)	0.0044
≤245	11/40 (28%)	1/13 (8%)	10/27 (37%)	0.036
>245	29/40 (73%)	12/13 (92%)	17/27 (63%)	..
Hypersensitive troponin I, pg/mL	3.4 (1.1-9.1)	3.3 (3.0-163.0)	3.5 (0.7-5.4)	0.08
>28 (99th percentile)	5/41 (12%)	4/13 (31%)	1/28 (4%)	0.017
Procalcitonin, ng/mL	0.1 (0.1-0.1)	0.1 (0.1-0.4)	0.1 (0.1-0.1)	0.031
<0.1	27/39 (69%)	6/12 (50%)	21/27 (78%)	0.0029
≥0.1 to <0.25	7/39 (18%)	3/12 (25%)	4/27 (15%)	..
≥0.25 to <0.5	2/39 (5%)	0/12	2/27 (7%)	..
≥0.5	3/39 (8%)	3/12 (25%)*	0/27	..
Bilateral involvement of chest radiographs	40/41 (98%)	13/13 (100%)	27/28 (96%)	0.68
Cycle threshold of respiratory tract	32.2 (31.0-34.5)	31.1 (30.0-33.5)	32.2 (31.1-34.7)	0.39

Data are median (IQR) or n/N (%), where N is the total number of patients with available data. p values comparing ICU care and no ICU care are from χ^2 , Fisher's exact test, or Mann-Whitney U test. 2019-nCoV=2019 novel coronavirus. ICU=intensive care unit. *Complicated typical secondary infection during the first hospitalisation.

Table 2: Laboratory findings of patients infected with 2019-nCoV on admission to hospital

プロカルシトニンは混合感染には有効でしょうか？